Department of Hematology and Medical Oncology and Hemophilia of Georgia Center for Bleeding & Clotting Disorders of Emory, Emory University School of Medicine, Atlanta, GA, USA.
Department of Infection Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK.
Haemophilia. 2021 Feb;27 Suppl 3:37-45. doi: 10.1111/hae.14013. Epub 2020 Jun 1.
With the introduction of clotting factor concentrates in the early 1970s, significant improvements in quality of life and life expectancy of persons with haemophilia (PWH) were realized. Unfortunately, as a result of transmission of HIV and hepatitis C virus (HCV) by contaminated concentrates in the 1980s, many of these gains were lost. Now with four decades of PWH unexposed to contaminated factor products and current treatments capable of suppressing and eliminating HIV and HCV, respectively, the survival rate is once again increasing. In addition to the usual comorbidities associated with advanced age in the general population, several specific issues occur in patients with bleeding disorders. This manuscript explores the incidence and management of the comorbidities of the ageing PWH with a focus on cardiovascular disease and osteoporosis.
随着 20 世纪 70 年代凝血因子浓缩物的引入，血友病患者（PWH）的生活质量和预期寿命得到了显著提高。不幸的是，由于 20 世纪 80 年代受污染浓缩物传播艾滋病毒和丙型肝炎病毒（HCV），这些收益中的许多都丧失了。如今，已有四代 PWH 未接触过受污染的因子产品，且目前的治疗方法分别能够抑制和消除 HIV 和 HCV，因此，存活率再次上升。除了普通人群中与高龄相关的常见合并症外，出血性疾病患者还会出现一些特定问题。本文探讨了年龄较大的 PWH 合并症的发生率和管理，重点关注心血管疾病和骨质疏松症。
